Composition for treating chronic pulmonary disease, comprising exosome derived from thrombin-treated stem cell
US10723997B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2017 |
| Grant date | Jul 28, 2020 |
| Priority date | — |
| Expiry date | Mar 30, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/734
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating chronic pulmonary disease, a pharmaceutical formulation containing the same, and a method for preparing the same, the composition comprising as an active ingredient an exosome derived from thrombin-treated stem cells. The therapeutic agent is advantageous in that since the therapeutic agent is a cell-free preparation, the risk of carcinogenesis is low and there is no problem of transplant rejection reaction, and furthermore, there is no possibility of causing the occlusion of the microvascular system upon systemic administration, and since the therapeutic agent is a non-cell separating material, it is possible to develop a pharmaceutical agent as an off-the-shelf product, thereby reducing the manufacturing cost, and the therapeutic agent has an excellent therapeutic effect for chronic pulmonary disease with a low concentration of exosome by virtue of the thrombin treatment effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.